# Vyvanse (lisdexamfetamine dimesylate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lisdexamfetamine

> The FDA approved Vyvanse (lisdexamfetamine dimesylate), sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), on January 28, 2017.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Vyvanse (lisdexamfetamine dimesylate) |
| Codes |  |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | priority review |

## Timeline

### January 28, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208510 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20170128, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product VYVANSE (LISDEXAMFETAMINE DIMESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208510%22

### July 29, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208510 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20210729, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product VYVANSE (LISDEXAMFETAMINE DIMESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208510%22
- openFDA Drugs@FDA: "NDA021977 SUPPL-46 (Efficacy): submission_status AP, submission_status_date 20210729, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product VYVANSE (LISDEXAMFETAMINE DIMESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021977%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lisdexamfetamine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vyvanse (lisdexamfetamine dimesylate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lisdexamfetamine

```bibtex
@misc{secapidev_pdufa_lisdexamfetamine_20261116,
  title        = {Vyvanse (lisdexamfetamine dimesylate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lisdexamfetamine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lisdexamfetamine_20261116","title":"Vyvanse (lisdexamfetamine dimesylate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lisdexamfetamine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
